Roche's cobas HPV Test receives FDA approval for cervical cancer screening

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This test will help physicians make early, more accurate decisions about patient care, which may prevent many women from developing this deadly disease.

The cobas HPV Test is the only FDA-approved cervical cancer screening test that allows HPV 16 and 18 genotyping concurrently with high-risk HPV testing. It individually identifies genotypes 16 and 18, the two highest-risk HPV genotypes responsible for more than 70 percent of cervical cancer cases, while simultaneously detecting 12 other high risk HPV genotypes. The approval was based on data from the ATHENA study involving more than 47,000 women in the U.S. Results demonstrated that 1 in 10 women, age 30 and older, who tested positive for HPV 16 and/or 18 by the cobas HPV Test actually had cervical pre-cancer even though they showed normal results with the Pap test.

"The FDA approval of the cobas HPV Test demonstrates the value of simultaneous HPV 16 and 18 genotyping in cervical cancer screening," said Daniel O'Day, Chief Operating Officer of Roche Diagnostics. "We look forward to working with laboratories and physicians to introduce the cobas HPV Test into routine cervical cancer screening."

More than 55 million Pap cytology ("Pap smear") tests are performed in the U.S. annually. Current guidelines for screening allow for either cytology or cytology plus HPV testing to determine the risk of cervical cancer. However, HPV testing, and 16 and 18 genotyping in particular, identifies more women at risk earlier than Pap cytology testing alone.

"Screening for high-risk HPV genotypes provides important additive information to Pap testing, and screening for the two highest risk types, HPV 16 and 18, can provide predictive information about a woman's risk for having cervical pre-cancer or cancer," said Mark H. Stoler, MD, Professor and Associate Director of Surgical Pathology and Cytopathology, at the University of Virginia Health System. "The cobas HPV Test provides physicians with a validated tool that helps them make early and more informed decisions regarding patient care."

SOURCE Roche

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Roche Diagnostics Limited. (2018, July 27). Roche's cobas HPV Test receives FDA approval for cervical cancer screening. News-Medical. Retrieved on November 25, 2020 from https://www.news-medical.net/news/20110420/Roches-cobas-HPV-Test-receives-FDA-approval-for-cervical-cancer-screening.aspx.

  • MLA

    Roche Diagnostics Limited. "Roche's cobas HPV Test receives FDA approval for cervical cancer screening". News-Medical. 25 November 2020. <https://www.news-medical.net/news/20110420/Roches-cobas-HPV-Test-receives-FDA-approval-for-cervical-cancer-screening.aspx>.

  • Chicago

    Roche Diagnostics Limited. "Roche's cobas HPV Test receives FDA approval for cervical cancer screening". News-Medical. https://www.news-medical.net/news/20110420/Roches-cobas-HPV-Test-receives-FDA-approval-for-cervical-cancer-screening.aspx. (accessed November 25, 2020).

  • Harvard

    Roche Diagnostics Limited. 2018. Roche's cobas HPV Test receives FDA approval for cervical cancer screening. News-Medical, viewed 25 November 2020, https://www.news-medical.net/news/20110420/Roches-cobas-HPV-Test-receives-FDA-approval-for-cervical-cancer-screening.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Roche announces acquisition of Signature Diagnostics